New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
09:07 EDTSRPTSarepta must enhance dataset for acceptable NDA filing, says Janney Capital
Janney Capital noted that the FDA said Sarepta's current dataset is not strong enough alone to file an adequate NDA for eteplirsen for Duchenne Muscular Dystrophy. The FDA suggested a fourth muscle biopsy in Study 202 patients, but Janney believes the company may be challenged to convince patients to undergo such surgeries. The firm maintains its Sell rating and $10 fair value estimate on shares of Sarepta.
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
09:01 EDTSRPTSarepta enters into partnership with Flagship Biosciences
Sarepta Therapeutics and Flagship Biosciences announced a multi-year, multi-product partnership for the development of automated quantitative endpoint measurements in muscular dystrophy to support the advancement of Sarepta’s Duchenne muscular dystrophy drug pipeline, including its lead candidate, eteplirsen. This newly established collaboration with Flagship demonstrates Sarepta’s commitment to enhancing the objective measurement of dystrophin in tissue samples for its growing pipeline of RNA-based therapeutics to treat DMD.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use